Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
07
10
2018
accepted:
18
03
2019
revised:
30
04
2019
pubmed:
11
4
2019
medline:
19
10
2019
entrez:
11
4
2019
Statut:
epublish
Résumé
Although considerable evidence supports that misfolded prion protein (PrPSc) is the principal component of "prions", underpinning both transmissibility and neurotoxicity, clear consensus around a number of fundamental aspects of pathogenesis has not been achieved, including the time of appearance of neurotoxic species during disease evolution. Utilizing a recently reported electrophysiology paradigm, we assessed the acute synaptotoxicity of ex vivo PrPSc prepared as crude homogenates from brains of M1000 infected wild-type mice (cM1000) harvested at time-points representing 30%, 50%, 70% and 100% of the terminal stage of disease (TSD). Acute synaptotoxicity was assessed by measuring the capacity of cM1000 to impair hippocampal CA1 region long-term potentiation (LTP) and post-tetanic potentiation (PTP) in explant slices. Of particular note, cM1000 from 30% of the TSD was able to cause significant impairment of LTP and PTP, with the induced failure of LTP increasing over subsequent time-points while the capacity of cM1000 to induce PTP failure appeared maximal even at this early stage of disease progression. Evidence that the synaptotoxicity directly related to PrP species was demonstrated by the significant rescue of LTP dysfunction at each time-point through immuno-depletion of >50% of total PrP species from cM1000 preparations. Moreover, similar to our previous observations at the terminal stage of M1000 prion disease, size fractionation chromatography revealed that capacity for acute synpatotoxicity correlated with predominance of oligomeric PrP species in infected brains across all time points, with the profile appearing maximised by 50% of the TSD. Using enhanced sensitivity western blotting, modestly proteinase K (PK)-resistant PrPSc was detectable at very low levels in cM1000 at 30% of the TSD, becoming robustly detectable by 70% of the TSD at which time substantial levels of highly PK-resistant PrPSc was also evident. Further illustrating the biochemical evolution of acutely synaptotoxic species the synaptotoxicity of cM1000 from 30%, 50% and 70% of the TSD, but not at 100% TSD, was abolished by digestion of immuno-captured PrP species with mild PK treatment (5μg/ml for an hour at 37°C), demonstrating that the predominant synaptotoxic PrPSc species up to and including 70% of the TSD were proteinase-sensitive. Overall, these findings in combination with our previous assessments of transmitting prions support that synaptotoxic and infectious M1000 PrPSc species co-exist from at least 30% of the TSD, simultaneously increasing thereafter, albeit with eventual plateauing of transmitting conformers.
Identifiants
pubmed: 30970042
doi: 10.1371/journal.ppat.1007712
pii: PPATHOGENS-D-18-01949
pmc: PMC6490942
doi:
Substances chimiques
PrPSc Proteins
0
Prions
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007712Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biol Chem. 2007 Mar 2;282(9):6300-7
pubmed: 17210575
Lancet. 1961 Jun 24;1(7191):1378-9
pubmed: 13692303
PLoS Pathog. 2015 May 07;11(5):e1004745
pubmed: 25951168
J Virol. 2013 Aug;87(15):8745-55
pubmed: 23740992
J Am Chem Soc. 2013 Jul 17;135(28):10533-41
pubmed: 23781904
PLoS Pathog. 2011 Sep;7(9):e1002242
pubmed: 21931554
Antioxid Redox Signal. 2012 Dec 1;17(11):1590-609
pubmed: 22114878
PLoS Pathog. 2018 Aug 8;14(8):e1007214
pubmed: 30089152
EMBO J. 2011 Jul 08;30(15):3065-77
pubmed: 21743439
Sci Rep. 2015 Dec 03;5:17742
pubmed: 26631638
Nat Rev Neurosci. 2014 Apr;15(4):209-16
pubmed: 24646669
Brain Res Bull. 2006 Jan 30;68(5):346-54
pubmed: 16377442
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3501-6
pubmed: 15741275
J Exp Med. 2016 May 30;213(6):1047-59
pubmed: 27185853
Neuropathol Appl Neurobiol. 2000 Feb;26(1):41-54
pubmed: 10736066
Neurobiol Dis. 2005 Nov;20(2):336-46
pubmed: 16242640
Lancet. 2004 Jan 3;363(9402):51-61
pubmed: 14723996
Eur J Neurosci. 2003 May;17(10):2147-55
pubmed: 12786981
Neuroscience. 1997 Oct;80(3):685-96
pubmed: 9276486
J Pathol. 2009 Sep;219(1):123-30
pubmed: 19479969
Nature. 2005 Sep 8;437(7056):257-61
pubmed: 16148934
Ann Neurol. 1979 Jun;5(6):581-4
pubmed: 382976
Neurobiol Dis. 1998 Sep;5(3):188-95
pubmed: 9848090
J Virol. 2015 Dec;89(24):12418-26
pubmed: 26423957
J Cereb Blood Flow Metab. 2000 Nov;20(11):1529-36
pubmed: 11083227
Nat Neurosci. 2012 Jun 26;15(7):936-9
pubmed: 22735515
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10248-53
pubmed: 10963685
ACS Chem Neurosci. 2010 Nov 17;1(11):720-7
pubmed: 22778809
Ann Neurol. 1982 Apr;11(4):353-8
pubmed: 6808890
Science. 1997 Oct 10;278(5336):245-51
pubmed: 9323196
Ageing Res Rev. 2017 Jul;36:156-164
pubmed: 28450269
Ann Neurol. 2010 Aug;68(2):162-72
pubmed: 20695009
EMBO J. 1996 Mar 15;15(6):1255-64
pubmed: 8635458
Neuroreport. 2001 Jul 20;12(10):2147-53
pubmed: 11447324
Mol Neurodegener. 2012 Apr 26;7:18
pubmed: 22534096
Nature. 2011 Feb 24;470(7335):540-2
pubmed: 21350487
J Gen Virol. 2005 Oct;86(Pt 10):2913-2923
pubmed: 16186247
J Virol. 2013 Mar;87(5):2535-48
pubmed: 23255799
Nat Commun. 2014 Jul 09;5:4347
pubmed: 25005024
PLoS Pathog. 2010 Apr 15;6(4):e1000859
pubmed: 20419156
Int J Biochem Cell Biol. 2008;40(12):2793-801
pubmed: 18590830
Cell Mol Life Sci. 2016 Feb;73(3):667-83
pubmed: 26298290
J Virol. 2002 Mar;76(5):2510-7
pubmed: 11836429